SEZGİ ŞAHİN DUYAR, AYDIN YILMAZ, FUNDA DEMİRAĞ, YURDANUR ERDOĞAN, ÜLKÜ YAZICI, JALE KARAKAYA

The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma

Background/aim: Alpha-methylacyl-CoA racemase (AMACR), an intracellular enzyme involved in lipid metabolism, has emerged as an immunohistochemical marker for many types of cancer. Recent studies about the role of lipid metabolism in pathogenesis of mesothelioma have brought up some positive results. This study was conducted to investigate AMACR expression in the diagnosis of malignant pleural mesothelioma (MPM) and the correlation of this marker with clinical characteristics and survival. Materials and methods: The clinicopathologic characteristics and resection materials of 71 patients were reviewed retrospectively. AMACR expression was evaluated immunohistochemically. The correlations among AMACR expression, clinicopathologic factors, and survival were investigated. Results: AMACR expression was detected in 42.3% of the study group. The specificity and sensitivity of AMACR immunostaining in detecting mesothelioma were 41.1% and 42.3%, respectively. AMACR-positive and negative groups were similar for age, sex, smoking history, tumor diameter, lymph node involvement, differentiation, T-N factor, and stage. Overall survival was not significantly different between the groups, either. Conclusion: The sensitivity of immunostaining was not high enough to use AMACR as a diagnostic tool in MPM. AMACR expression did not have a prognostic value in MPM, either.

Anahtar Kelimeler:

AMACR, carcinogenesis, mesothelioma

The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma

Keywords:

AMACR, carcinogenesis, mesothelioma,

PDF

___

Zomer AW, van Der Burg B, Jansen GA, Wanders RJ, Poll
The BT, van Der Saag PT. Pristanic acid and phytanic
acid: naturally occurring ligands for the nuclear receptor
peroxisome proliferator-activated receptor. J Lipid Res 2000; 41: 1801–1807.
Nassar A, Amin MB, Sexton DG, Cohen C. Utility of alpha- methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morphol 2005; 13: 252–255.
Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Research 2002; 62: 2220–2226.
Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, Xu J, Chu PG. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 2003; 34: 792–796.
Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108: 1122–1128.
Shilo K, Dracheva T, Mani H, Fukuoka J, Sesterhenn IA, Chu WS, Shih JH, Jen J, Travis WD, Franks TJ. Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis. Arch Pathol Lab Med 2007; 131: 1555–1560.
Erdogan Y, Demirag F, Duyar SS, Yilmaz A, Yazıcı Ü, Aydoğdu K. The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) in squamous cell carcinoma and adenocarcinoma of lung. Acta Chir Belg 2011; 113: 263–269.
Li MY, Yuan H, Ma LT, Kong AW, Hsin MK, Yip JH, Underwood MJ, Chen GG. Roles of PPAR{alpha} and PPAR {gamma} in the development of non-small cell lung cancer. Am J Respir Cell Mol Biol 2010; doi:10.1165/rcmb.2009-0349OC.
Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M, Vedvick TS, Leslie KB, Badaro R, Reed SG. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000; 60: 1677–1682.
Daugherty SE, Platz EA, Shugart YY, Fallin MD, Isaacs WB, Chatterjee N, Welch R, Huang WY, Hayes RB. Variants in the alpha-methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2007; 16: 1536–1542.
Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-methylacyl-CoA racemase: a novel tumor marker overexpressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002; 26: 926–931.
Tretiakova MS, Sahoo S, Takahashi M, Turkyilmaz M, Vogelzang NJ, Lin F, Krausz T, Teh BT, Yang XJ. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol 2004; 28: 69–76.
Went PT, Sauter G, Oberholzer M, Bubendorf L. Abundant expression of AMACR in many distinct tumour types. Pathology 2006; 38: 426–432.
Halsey MA, Calder KB, Mathew R, Schlauder S, Morgan MB. Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms. J Cutan Pathol 2010; 37: 446–451.
Comin CE, Novelli L, Boddi V, Paglierani M, Dini S. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating mesothelioma from pulmonary adenocarcinoma. Hum Pathol 2001; 32: 529–532.
Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317–1331.
Witkiewicz AK, Varambally S, Shen R, Mehra R, Sabel MS, Ghosh D, Chinnaiyan AM, Rubin MA, Kleer CG. Alpha- methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. Cancer Epidemiol Biomarkers Prev 2005; 14: 1418–1423.
Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter H, Mattfeldt T, Hautmann RE, Gschwend JE, Barrette TR et al. α-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 2002; 161: 841–848.
Hiddinga BI, Surmont VF, Van Meerbeeck JP. Management of malignant pleural mesothelioma: have we made any progress? Panminerva Med 2013; 55: 157–173.